12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins

Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins

Infectious disease serology is one of the most heavily emphasized disciplines in the Philippine Medical Technologists Licensure Examination (MTLE) and clinical diagnostic laboratory practice. Serological assays detect either specific circulating microbial antigens or the host's humoral antibody response. Accurately staging syphilis infections, mapping the serological kinetics of viral hepatitis B, executing the CDC/CLSI 4th-generation HIV diagnostic algorithm, differentiating primary from secondary dengue infections, and interpreting classical febrile agglutinin panels require deep comprehension of analytical principles, specimen requirements, and immunologic window periods.

---

1. Syphilis Serology: Non-Treponemal Tests, Treponemal Tests, and Diagnostic Algorithms

Syphilis is a chronic, systemic sexually transmitted infection caused by the spirochete Treponema pallidum subsp. pallidum. Because the organism cannot be cultured on artificial microbiological media, laboratory diagnosis relies heavily on serological methods divided into non-treponemal and treponemal assays.

                                  ┌────────────────────────────────────────┐
                                  │      Syphilis Serodiagnostic Tests     │
                                  └───────────────────┬────────────────────┘
                                                      │
                   ┌──────────────────────────────────┴──────────────────────────────────┐
                   ▼                                                                     ▼
    ┌─────────────────────────────┐                                       ┌─────────────────────────────┐
    │    Non-Treponemal Tests     │                                       │      Treponemal Tests       │
    │  (Anti-Cardiolipin Reagin)  │                                       │ (Specific anti-T. pallidum) │
    └──────────────┬──────────────┘                                       └──────────────┬──────────────┘
                   │                                                                     │
    ┌──────────────┴──────────────┐                                       ┌──────────────┴──────────────┐
    ▼                             ▼                                       ▼                             ▼
  VDRL                          RPR                                     FTA-ABS                       TP-PA
• Microscopic flocculation   • Macroscopic flocculation              • Reiter treponeme sorbent    • Gelatin particle
• 56°C for 30 min heat       • Unheated serum/plasma                 • Nichol strain slide           agglutination
• Fresh daily antigen        • Choline chloride (inactivates C')     • FITC-labeled AHG            • Simpler, objective
• Rotated: 180 rpm, 4 min    • Charcoal particles for contrast       • Lifelong positivity         • Confirmatory
• Gold standard for CSF!     • Rotated: 100 rpm, 8 min               • Cannot monitor therapy      • Confirmatory

Non-Treponemal Serological Tests (VDRL and RPR)

Non-treponemal tests detect reagin—a mixture of IgM and IgG antibodies directed against cardiolipin-lecithin-cholesterol antigens. Cardiolipin is a normal mitochondrial phospholipid released into the circulation following host cell membrane destruction caused by the invasive spirochetes, combined with lipid moieties shed from treponemal outer membranes.

1. Venereal Disease Research Laboratory (VDRL):

   • Methodology: Microscopic flocculation test.
   • Specimen Preparation: Serum must be heat-inactivated at $56^\circ\text{C}$ for 30 minutes in a water bath to destroy endogenous complement components that cause non-specific lysis or clumping. If testing is delayed beyond 4 hours, serum must be re-inactivated at $56^\circ\text{C}$ for 10 minutes.
   • Antigen Preparation: Buffered saline solution containing 0.03% cardiolipin, 0.21% lecithin, and 0.9% cholesterol. Reagent antigen must be prepared fresh daily; once reconstituted, it remains chemically stable for only 8 hours.
   • Test Mechanics: A calibrated dispensing needle delivering exactly 60 drops/mL ($1/60\text{ mL}$ or $\approx 17\ \mu\text{L}$ per drop) dispenses antigen into ceramic ring paraffin-coated glass slides containing $50\ \mu\text{L}$ of heat-inactivated serum. Rotated on an orbital rotator at $180\text{ rpm}$ for 4 minutes.
   • Examination: Microscopic evaluation under low power ($100\times$). Non-reactive shows a smooth suspension of needle-like crystals; reactive shows distinct microscopic clumped aggregates.
   • Cerebrospinal Fluid (CSF) Testing: VDRL is the only internationally recognized and approved non-treponemal test for cerebrospinal fluid (CSF) in suspected neurosyphilis (termed VDRL-CSF). Unheated CSF is used; a positive CSF VDRL is diagnostic of neurosyphilis.

2. Rapid Plasma Reagin (RPR):

   • Methodology: Macroscopic flocculation test.
   • Specimen Preparation: Performed on unheated serum or EDTA plasma.
   • Antigen Formulation: Modified VDRL cardiolipin antigen containing:
     • Choline chloride ($10\%$): Chemically inactivates endogenous complement, completely eliminating the need for heat inactivation.
     • EDTA ($0.0125\text{ M}$): Chelates trace heavy metals, stabilizing the antigen suspension for several months.
     • Micronized Charcoal Particles: Trapped within flocculating lipid lattices, allowing clear macroscopic visualization against white plastic-coated cards without a microscope.
     • Thimerosal: Chemical bacteriostatic preservative.
   • Test Mechanics: Specimen ($50\ \mu\text{L}$) spread over an 18-mm card circle; antigen delivered via a blunt 20-gauge needle delivering 60 drops/mL ($1/60\text{ mL}$) held vertically. Rotated on a mechanical rotator at $100\text{ rpm}$ for exactly 8 minutes inside a humidified chamber (to prevent edge drying artifacts).
   • Contraindication: RPR is strictly contraindicated for CSF testing because colloidal charcoal particles aggregate non-specifically in spinal fluid.

3. Quantitative Titers and Therapeutic Monitoring:

   • Reactive specimens in non-treponemal tests must be serially diluted two-fold ($1:1, 1:2, 1:4, 1:8, 1:16, 1:32\dots$) to determine the endpoint titer (the highest dilution demonstrating definite flocculation).
   • Non-treponemal titers correlate directly with disease activity: high titers (≥ 1:32) occur during secondary syphilis. Successful antibiotic treatment (e.g., Benzathine penicillin G) is clinically defined by a four-fold (two-tube) decline in titer (e.g., from $1:32$ down to $1:8$ or $1:4$) within 6 to 12 months after therapy.

4. Biologic False Positives (BFP):

   • Because reagin targets cardiolipin rather than treponemal proteins, false-positive reactions occur in conditions involving tissue destruction or autoimmune anti-phospholipid antibodies:
   • Acute BFP ($<6\text{ months}$): Recent viral infections (Epstein-Barr virus, hepatitis, measles, varicella), malaria, pregnancy, extensive burns, and recent immunizations.
   • Chronic BFP ($>6\text{ months}$): Systemic Lupus Erythematosus (anti-cardiolipin antibodies / lupus anticoagulant), rheumatoid arthritis, Hashimoto thyroiditis, leprosy, intravenous drug addiction, and advanced aging ($>75\text{ years}$). Treponemal confirmatory testing is mandatory to rule out syphilis.

Treponemal Confirmatory Tests

Treponemal tests detect specific antibodies directed against structural proteins of Treponema pallidum:

• Fluorescent Treponemal Antibody Absorption (FTA-ABS):
  • Sorbent Pre-treatment: Patient serum is diluted $1:5$ with an extract of non-pathogenic Reiter treponemes (Treponema phagedenis) termed sorbent. Sorbent binds and neutralizes cross-reacting non-pathogenic antibodies shared with normal oral and genital saprophytic treponemes.
  • Slide Reaction: Absorbed serum is overlaid onto microscope slides fixed with pathogenic Nichol strain T. pallidum. Specific anti-treponemal antibodies bind the spirochetes.
  • Visualization: Slides are washed and stained with FITC-labeled anti-human globulin. Viewed under a fluorescence microscope ($400\times$). Graded $1+$ to $4+$ apple-green fluorescence.
  • Clinical Profile: Highly sensitive and specific; becomes positive early in primary syphilis and remains positive for life in $>85\text{--}90\%$ of patients regardless of successful treatment. Thus, FTA-ABS cannot be used to monitor therapeutic efficacy or diagnose re-infection.
• Treponema pallidum Particle Agglutination (TP-PA):
  • Utilizes colored avian gelatin particles sensitized with purified T. pallidum antigens. In the presence of treponemal antibodies, sensitized particles settle into an even, diffuse mat across microtiter well bottoms; unsensitized controls settle as a compact button. Eliminates subjective fluorescence grading.

Traditional Versus Reverse Syphilis Screening Algorithm

• Traditional Algorithm: Serum screened initially with a non-treponemal test (RPR or VDRL). Reactive samples are confirmed with a treponemal test (TP-PA or FTA-ABS). Fails to detect early primary or late latent/tertiary syphilis where non-treponemal titers are low or non-reactive.
• Reverse Sequence Screening Algorithm: Utilized in high-volume automated laboratories. Serum is screened first with an automated treponemal immunoassay (EIA or CLIA). If reactive, reflexed to a quantitative non-treponemal test (RPR):
  • EIA Reactive + RPR Reactive: Active, untreated, or recently treated syphilis.
  • EIA Reactive + RPR Non-Reactive: Discrepant result. Must be resolved by testing with a second, distinct treponemal assay (TP-PA):
    • If TP-PA is reactive: Confirms past, successfully treated syphilis or late latent/tertiary infection.
    • If TP-PA is non-reactive: The initial EIA screen is declared a false-positive result.

---

2. Viral Hepatitis Serological Profiles: Hepatitis B, A, and C

Viral hepatitis diagnostics depend on tracking the dynamic appearance and clearance of viral antigens and host antibodies:

  Concentration / Titer
    ▲
    │        HBsAg                HBeAg             Anti-HBc Total
    │      ┌───────┐           ┌────────┐     ┌────────────────────────► (Persists for Life)
    │     ┌┘       └┐         ┌┘        └┐   ┌┘
    │    ┌┘         └┐       ┌┘          └┐ ┌┘  IgM Anti-HBc
    │   ┌┘           └┐     ┌┘            └┌┘    ┌────────┐
    │  ┌┘             └┐   ┌┘             ┌┴┐   ┌┘        └┐
    │ ┌┘               └┐ ┌┘             ┌┘ └┐ ┌┘          └┐      Anti-HBs
    │ │                 └─┘              │   └─┘            └┐  ┌─────────────► (Protective Immunity)
    └─┴──────────────────┬───────────────┴───────────────────┴──┴───────────────────►
      0   4    8   12   16   20   24   28   32   36   40   44   48   Weeks
                         ▲               ▲
                         │◄─ CORE WINDOW─►│
                         (HBsAg neg, Anti-HBs neg; IgM Anti-HBc sole marker)

Hepatitis B Virus (HBV) Biomarkers

• 1. Hepatitis B Surface Antigen (HBsAg): The first serological marker detectable in serum, appearing 1 to 10 weeks after exposure. Its presence signifies active viral infection (acute or chronic) and high infectivity. Persistence of HBsAg for greater than 6 months defines chronic HBV infection.
• 2. Hepatitis B e-Antigen (HBeAg): Soluble secretory nucleocapsid antigen that appears shortly after HBsAg. Indicates active viral replication, high infectivity, and active hepatic disease. Persistence indicates high risk of cirrhosis and hepatocellular carcinoma.
• 3. Anti-HBe (Antibody to HBeAg): Appears upon seroconversion when HBeAg disappears. Signifies waning viral replication and transitioning into a low-infectivity carrier state.
• 4. Total Anti-HBc (Total Antibody to Core Antigen): Measures both IgM and IgG directed against the HBV core antigen. Appears early (weeks 4–8) and persists for life in anyone who has ever contracted natural HBV. It is absent in individuals whose immunity is derived solely from recombinant vaccination.
• 5. IgM Anti-HBc: The hallmark marker of acute or recent HBV infection (persists for 4 to 6 months). It is the sole detectable serological marker during the "Core Window" (or window period)—the interval when HBsAg has fallen below analytical detection limits, but protective neutralizing anti-HBs has not yet risen to measurable titers.
• 6. Anti-HBs (Antibody to Surface Antigen): Neutralizing protective antibody that confers long-term clinical immunity. A titer $\ge 10\text{ mIU/mL}$ indicates protection. Indicates clinical recovery from natural infection or successful response to HBV vaccination.

HBV Serological Interpretation Matrix (MTLE High-Yield)

Hepatitis A and C Serology

• Hepatitis A Virus (HAV): Non-enveloped single-stranded RNA picornavirus transmitted via the fecal-oral route:
  • Anti-HAV IgM: Diagnostic marker of acute Hepatitis A infection. Appears at symptom onset, peaks within 2 to 3 weeks, and declines within 3 to 6 months.
  • Anti-HAV Total / IgG: Persists indefinitely, indicating past infection or vaccine-induced protective immunity.
• Hepatitis C Virus (HCV): Enveloped single-stranded RNA flavivirus transmitted parenterally:
  • Anti-HCV Screening: Detected by 3rd-generation chemiluminescent or enzyme immunoassays. Antibodies appear 8 to 12 weeks post-exposure.
  • Confirmatory Testing: A positive anti-HCV screen must be confirmed by HCV RNA qualitative or quantitative Nucleic Acid Testing (NAT) to differentiate active, ongoing viremia from spontaneously cleared or successfully treated infection.

---

3. Human Immunodeficiency Virus (HIV): Diagnostic Algorithms and Monitoring

HIV-1 and HIV-2 (Retroviridae, Lentivirus) selectively infect and deplete helper T-lymphocytes bearing the CD4 receptor and chemokine coreceptors CCR5 or CXCR4.

CDC / CLSI 4th-Generation HIV Diagnostic Algorithm

Modern diagnostic guidelines mandate an objective multi-step testing algorithm to minimize window periods down to 14–20 days:

                                    [ Step 1: Initial Screen ]
                           4th-Gen Combination Immunoassay (Ag/Ab)
                                 (HIV-1/2 Ab + HIV-1 p24 Ag)
                                             │
                         ┌───────────────────┴───────────────────┐
                         ▼                                       ▼
                    [ NEGATIVE ]                            [ REACTIVE ]
                 Report as Negative                              │
                                                                 ▼
                                                    [ Step 2: Differentiation ]
                                                    HIV-1 / HIV-2 Antibody Rapid
                                                        Differentiation Assay
                                                                 │
                 ┌───────────────────────────┬───────────────────┴───────────────────────────┐
                 ▼                           ▼                                               ▼
        HIV-1 (+) / HIV-2 (-)       HIV-1 (-) / HIV-2 (+)                           HIV-1 (-) or Indeterminate
                 │                           │                                      HIV-2 (-) or Indeterminate
                 ▼                           ▼                                               │
         [ HIV-1 Infection ]         [ HIV-2 Infection ]                                     ▼
                                                                                    [ Step 3: Reflex NAT ]
                                                                                   HIV-1 RNA Qualitative NAT
                                                                                             │
                                                                             ┌───────────────┴───────────────┐
                                                                             ▼                               ▼
                                                                        NAT (+)                         NAT (-)
                                                                 [ Acute Primary HIV-1 ]           [ False-Positive ]
                                                                  (Early Seroconversion)           Initial Step 1 CIA

• Historical Western Blot Criteria: Electrophoretically separated viral proteins blotted onto nitrocellulose. The CDC/ASTPHLD criteria require the presence of at least two of the three following diagnostic bands to report a positive Western Blot: p24 (gag capsid), gp41 (env transmembrane glycoprotein), or gp120 / gp160 (env surface / precursor glycoproteins).
• Flow Cytometric Immune Staging: Absolute CD4+ helper T-cell counts are enumerated via flow cytometry (normal: $500\text{--}1,500/\mu\text{L}$; CD4/CD8 ratio $>1.0$). Progression to Acquired Immunodeficiency Syndrome (AIDS) is clinically established when the absolute CD4+ count drops below $200\text{ cells/}\mu\text{L}$ (or CD4 percentage $<14\%$) or upon diagnosis of an AIDS-defining opportunistic condition (Pneumocystis jirovecii pneumonia, cerebral toxoplasmosis, disseminated cryptococcosis).

---

4. Dengue Serology: NS1 Antigen Kinetics and Antibody-Dependent Enhancement

Dengue virus is a mosquito-borne flavivirus comprising four antigenically distinct serotypes (DENV-1, DENV-2, DENV-3, DENV-4) transmitted by Aedes aegypti and Aedes albopictus.

Dengue Diagnostic Biomarkers

• Non-Structural Protein 1 (NS1) Antigen:
  • Highly conserved, non-structural glycoprotein essential for viral RNA replication, secreted in high concentrations into peripheral blood during acute viremia.
  • Diagnostic Window: Detectable from Day 1 through Day 5 to 7 following fever onset. NS1 enables definitive diagnosis during the acute febrile window before the emergence of endogenous antibodies.
• Dengue IgM and IgG Capture ELISA Kinetics:
  • Primary Dengue Infection: IgM appears around day 4 to 5 of fever, peaks at 2 weeks, and persists for 2 to 3 months. Specific IgG appears late (day 10 to 14) at low-to-moderate titers.
  • Secondary Dengue Infection: Re-infection with a heterologous DENV serotype triggers an immediate, massive secondary anamnestic response. Dengue IgG titers soar rapidly within 24 to 48 hours, reaching titers $>1:2560$, while IgM titers remain blunted, low, or undetectable.
• Antibody-Dependent Enhancement (ADE) and Severe Dengue:
  • In secondary infection, pre-existing sub-neutralizing heterologous IgG antibodies cross-react with the new serotype. Instead of neutralizing the virus, the non-neutralizing IgG-virion immune complexes bind avidly to $Fc\gamma$ receptors on circulating monocytes and macrophages.
  • This promotes viral entry, leading to hyper-accelerated intracellular viral replication, massive macrophage activation, and a systemic "cytokine storm" ($TNF\text{-}\alpha, IL\text{-}6, IL\text{-}10, IFN\text{-}\gamma$). This causes extensive vascular endothelial hyperpermeability, marked plasma leakage, hemoconcentration (hematocrit increase $>20\%$, thrombocytopenia $<100,000/\mu\text{L}$), Dengue Hemorrhagic Fever (DHF), and life-threatening hypovolemic Dengue Shock Syndrome (DSS).

---

5. Febrile Agglutinins: Widal, Weil-Felix, and Brucella Assays

Febrile agglutinins are classical serological agglutination tests used to detect circulating serum antibodies against organisms causing acute prolonged febrile illnesses:

1. Widal Test (Salmonella enterica serovar Typhi):

   • Detects agglutinins against Salmonella surface antigens in patients suspected of having typhoid (enteric) fever:
   • Somatic O (O-Ag): Lipopolysaccharide cell wall antigen. O agglutinins appear early (at the end of week 1), decline within 6 to 12 months, and indicate acute, active infection if titers are $\ge 1:160$ or show a four-fold increase in paired acute/convalescent sera.
   • Flagellar H (H-Ag): Heat-labile proteinaceous flagellar antigen. H agglutinins appear later (week 2 to 3), reach higher titers, persist for years, and frequently reflect past infection, anamnestic responses, or prior TAB vaccination (titer $\ge 1:160$).

2. Weil-Felix Reaction (Rickettsial Infections):

   • A presumptive serological agglutination assay that exploits antigenic cross-reactivity between human rickettsial antibodies and the somatic O polysaccharides of non-motile strains of Proteus (Proteus vulgaris OX-19 and OX-2, and Proteus mirabilis OX-K):

1. Brucella Agglutination Test:
   • Detects agglutinating antibodies against Brucella abortus, B. melitensis, and B. suis in patients with brucellosis (undulant fever). Highly susceptible to prozone artifacts caused by high concentrations of blocking non-agglutinating IgA or IgG; patient serum must be tested through serial dilutions up to at least $1:640\text{ to }1:1280$.